JP2013526705A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013526705A5 JP2013526705A5 JP2013510115A JP2013510115A JP2013526705A5 JP 2013526705 A5 JP2013526705 A5 JP 2013526705A5 JP 2013510115 A JP2013510115 A JP 2013510115A JP 2013510115 A JP2013510115 A JP 2013510115A JP 2013526705 A5 JP2013526705 A5 JP 2013526705A5
- Authority
- JP
- Japan
- Prior art keywords
- stem cell
- determining
- stem cells
- neurodegenerative disease
- contacting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 claims description 56
- 206010053643 Neurodegenerative disease Diseases 0.000 claims description 21
- 102000004965 antibodies Human genes 0.000 claims description 18
- 108090001123 antibodies Proteins 0.000 claims description 18
- 230000011987 methylation Effects 0.000 claims description 14
- 238000007069 methylation reaction Methods 0.000 claims description 14
- 102100012570 GFAP Human genes 0.000 claims description 10
- 101700069447 GFAP Proteins 0.000 claims description 10
- 101710008068 POU4F1 Proteins 0.000 claims description 10
- 101700079116 QSOX1 Proteins 0.000 claims description 10
- 101700006931 SOX2 Proteins 0.000 claims description 10
- -1 TuJ1 Proteins 0.000 claims description 9
- 239000002771 cell marker Substances 0.000 claims description 9
- 230000004069 differentiation Effects 0.000 claims description 9
- 239000003550 marker Substances 0.000 claims description 9
- 229930003270 Vitamin B Natural products 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 235000019156 vitamin B Nutrition 0.000 claims description 6
- 239000011720 vitamin B Substances 0.000 claims description 6
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 claims description 5
- 206010001897 Alzheimer's disease Diseases 0.000 claims description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 4
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims description 4
- 102000004889 Interleukin-6 Human genes 0.000 claims description 4
- 108090001005 Interleukin-6 Proteins 0.000 claims description 4
- 206010061536 Parkinson's disease Diseases 0.000 claims description 4
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 4
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 4
- 229940064128 L-methylfolate Drugs 0.000 claims description 3
- 235000007635 levomefolic acid Nutrition 0.000 claims description 3
- 239000011578 levomefolic acid Substances 0.000 claims description 3
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical group C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 claims description 3
- 229940100601 Interleukin-6 Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39532110P | 2010-05-11 | 2010-05-11 | |
| US61/395,321 | 2010-05-11 | ||
| PCT/US2011/033387 WO2011142952A1 (en) | 2010-05-11 | 2011-04-21 | Method of detecting and profiling progression of the risk of neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013526705A JP2013526705A (ja) | 2013-06-24 |
| JP2013526705A5 true JP2013526705A5 (el) | 2014-03-27 |
Family
ID=44914644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013510115A Pending JP2013526705A (ja) | 2010-05-11 | 2011-04-21 | 神経変性疾患のリスクの推移を検出およびプロファイリングする方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20130029998A1 (el) |
| EP (1) | EP2569625A4 (el) |
| JP (1) | JP2013526705A (el) |
| CA (1) | CA2795438A1 (el) |
| WO (1) | WO2011142952A1 (el) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10282875B2 (en) | 2015-12-11 | 2019-05-07 | International Business Machines Corporation | Graph-based analysis for bio-signal event sensing |
| JP6994469B2 (ja) | 2016-04-20 | 2022-02-04 | エアラン セル テクノロジーズ， インコーポレイテッド | Ｋ１８０ジメチル化ｈ１．０タンパク質に関連する組成物および方法 |
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| EP3700569A4 (en) | 2017-10-25 | 2021-08-25 | Aelan Cell Technologies, Inc. | H1.0K180ME2 ANTIBODIES, METHOD OF MANUFACTURING AND USES THEREOF |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11016A (en) * | 1854-06-06 | Method of turning hubs | ||
| US7025A (en) * | 1850-01-15 | Buckle | ||
| US20050037992A1 (en) * | 2003-07-22 | 2005-02-17 | John Lyons | Composition and method for treating neurological disorders |
| US8969313B2 (en) * | 2007-11-02 | 2015-03-03 | Agency For Science, Technology And Research | Methods and compounds for preventing and treating a tumour |
| US20110160399A1 (en) * | 2008-07-01 | 2011-06-30 | Nihon University | Histone modification inhibitor specific to target gene |
-
2011
- 2011-04-21 WO PCT/US2011/033387 patent/WO2011142952A1/en active Application Filing
- 2011-04-21 EP EP11780997.0A patent/EP2569625A4/en not_active Withdrawn
- 2011-04-21 JP JP2013510115A patent/JP2013526705A/ja active Pending
- 2011-04-21 US US13/640,545 patent/US20130029998A1/en not_active Abandoned
- 2011-04-21 CA CA2795438A patent/CA2795438A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Drummond et al. | Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease | |
| De Chiara et al. | Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice | |
| Musunuri et al. | Quantification of the brain proteome in Alzheimer’s disease using multiplexed mass spectrometry | |
| Villemagne et al. | In vivo tau imaging: obstacles and progress | |
| Cenini et al. | Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome | |
| Thorsell et al. | Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease | |
| JP2013526705A5 (el) | ||
| Hannaoui et al. | Prion propagation and toxicity occur in vitro with two-phase kinetics specific to strain and neuronal type | |
| Yu et al. | Magnesium modulates amyloid-β protein precursor trafficking and processing | |
| Tampellini et al. | Impaired β-amyloid secretion in Alzheimer's disease pathogenesis | |
| H Peden et al. | Molecular pathology in neurodegenerative diseases | |
| HRP20230186T1 (hr) | METODA PROCJENE RIZIKA OD PML-a | |
| HRP20140937T1 (hr) | POSTUPAK ZA OTKRIVANJE AĂź-SPECIFIÄŚNIH PROTUTIJELA U BIOLOŠKOM UZORKU | |
| Flores-Cuadrado et al. | Astrogliosis and sexually dimorphic neurodegeneration and microgliosis in the olfactory bulb in Parkinson’s disease | |
| Yamamoto et al. | Proteomic Identification of Protein Targets for 15-Deoxy-Δ12, 14-Prostaglandin J2 in Neuronal Plasma Membrane | |
| Izuo et al. | Toxicity in rat primary neurons through the cellular oxidative stress induced by the turn formation at positions 22 and 23 of Aβ42 | |
| WO2013096451A3 (en) | Methods for diagnosing alzheimer's disease | |
| Coskuner et al. | Adenosine triphosphate (ATP) reduces amyloid-β protein misfolding in vitro | |
| Liu et al. | Effects of lead exposure on the expression of amyloid β and phosphorylated tau proteins in the C57BL/6 mouse hippocampus at different life stages | |
| Weng et al. | Disrupted ubiquitin proteasome system underlying tau accumulation in Alzheimer’s disease | |
| WO2009100953A3 (en) | Diagnostic method | |
| Shen et al. | Proteomic profiling of cerebrum mitochondria, myelin sheath, and synaptosome revealed mitochondrial damage and synaptic impairments in association with 3× Tg‐AD mice model | |
| WO2011100396A3 (en) | Serum clusterin levels in systemic amyloidosis featuring cardiomyopathy | |
| Kim et al. | What is the clinical significance of cerebrospinal fluid biomarkers in Parkinson's disease? Is the significance diagnostic or prognostic? | |
| Ly et al. | Loss of activated CaMKII at the synapse underlies Alzheimer's disease memory loss. |